Chembio Announces Return of President and CEO John Sperzel
October 02 2017 - 8:50AM
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in
point-of-care (POC) diagnostic tests for infectious
diseases, today announced that President and Chief
Executive Officer, John Sperzel, has returned to work following a
medical leave of absence.
Katherine L. Davis, Chairman of Chembio’s Board
of Directors, stated, “The Board is delighted that John has
returned full time to his role as President and Chief Executive
Officer of Chembio. We are grateful for John’s recovery, for
his unwavering dedication to the company and his team during his
leave, and for the powerful leadership exhibited by acting CEO,
Sharon Klugewicz, and the executive leadership team. Sharon
and her team executed the strategy and maintained momentum during
John’s absence. We go forward stronger thanks to this team’s
intense effort and good will.”
Sperzel stated, “My recovery following heart
transplant surgery has gone very well and I am elated to return to
lead the Company. During my leave, I remained actively engaged in
major corporate decisions and we continued to advance our strategy
with a focus in three key areas: strengthening our core sexually
transmitted disease business, building a broad tropical and fever
disease portfolio, and building a global commercial team.”
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops,
manufactures, licenses and markets rapid diagnostic tests in the
growing $8.0 billion POC testing market. The Company markets its
products directly and through third-party distributors under
the brand names: DPP®, STAT-PAK® and SURE CHECK®.
Chembio has developed and patented
the DPP® technology platform, which offers significant
advantages over traditional POC lateral-flow technologies and
provides the Company with a significant pipeline of business
opportunities in the area of sexually transmitted disease, tropical
and fever disease, and technology collaborations.
Headquartered in Medford, NY, Chembio is
licensed by the U.S. Food and Drug Administration (FDA) as well as
the U.S. Department of Agriculture (USDA), and is certified for the
global market under the International Standards Organization (ISO)
directive 13485. Each of Chembio Diagnostic Systems, Inc. and
Chembio Diagnostics Malaysia Sdn Bhd is a wholly-owned subsidiary
of Chembio Diagnostics, Inc. For more information, please
visit: www.chembio.com.
Forward-Looking Statements
Statements contained herein that are not
historical facts may be forward-looking statements within the
meaning of the Securities Act of 1933, as amended.
Forward-looking statements include statements regarding the intent,
belief or current expectations of the Company and its
management. Such statements, which are estimates only,
reflect management's current views, are based on certain
assumptions, and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the
above forward-looking statements due to a number of important
factors, and will be dependent upon a variety of factors,
including, but not limited to Chembio's ability to
obtain additional financing and to obtain regulatory approvals
in a timely manner, as well as the demand for Chembio's
products. Chembio undertakes no obligation to publicly update
these forward-looking statements to reflect events or circumstances
that occur after the date hereof or to reflect any change in
Chembio's expectations with regard to these forward-looking
statements or the occurrence of unanticipated events. Factors
that may impact Chembio's success are more fully disclosed in
Chembio's most recent public filings with the U.S. Securities and
Exchange Commission.
Contact:
Vida Strategic Partners (investor relations)Stephanie C.
Diaz(415) 675-7401sdiaz@vidasp.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Sep 2023 to Sep 2024